1. Home
  2. Browse Decisions
  3. F.Supp.2d
  4. 933 F.Supp.2d
  5. 933 F.Supp.2d 751 (2013)
 

IN RE HUMAN GENOME SCIENCES INC. SECURITIES LITIG.

Civil Action No. RWT 11cv3231.

933 F.Supp.2d 751 (2013)

In re HUMAN GENOME SCIENCES INC. SECURITIES LITIGATION. This Document Relates to All Actions.

United States District Court, D. Maryland.

March 26, 2013.

Attorney(s) appearing for the Case

Dana Whitehead McKee, Gregory P. Care, Brown, Goldstein and Levy, LLP, Baltimore, MD, David R. Scott, Scott and Scott LLP, Colchester, CT, Deborah Clark Weintraub, Scott and Scott, LLP, New York, NY, Mary K. Blasy, Scott and Scott, LLP, San Diego, Matthew P. Montgomery, Scott and Scott, LLP, San Diego, CA, for Plaintiff.

David Clarke, Jr., James D. Mathias DLA Piper US LLP Baltimore, MD, Kenneth J.P Faehler, Dentons US, LLP, Washington, DC, Sandra D. Hauser, SNR Denton US, LLP, New York, NY, for Defendant.

MEMORANDUM OPINION

ROGER W. TITUS, District Judge.

Benlysta® is a drug developed and marketed by Defendants Human Genome Sciences, Inc. ("HGS") and Glaxo Smith Kline, PLC ("GSK") for the treatment of lupus. It was approved by the FDA in 2011, and was the first new treatment for lupus approved in 56 years. During several clinical trials involving more than 1,900 patients, Defendants learned that three participants had committed suicide. Defendants...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases